| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Childhood Leukemia
|
NCI
|
5R01CA120196-02
|
|
Mechanisms of T-Cell Leukemogenesis Induced by Notch1
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$305,900
|
|
Childhood Leukemia
|
NCI
|
5R01CA111778-04
|
|
Molecular Studies of Down Syndrome Leukemia
|
PERENTESIS, JOHN
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$231,698
|
|
Childhood Leukemia
|
NIMH
|
5R01MH067978-05
|
|
Maternal Viral Infection and Fetal Brain Development
|
PATTERSON, PAUL
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
CA
|
$307,210
|
|
Childhood Leukemia
|
NCI
|
5K08CA111399-04
|
|
Mouse model of infant acute megakaryocytic leukemia
|
RAFFEL, GLEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$134,379
|
|
Childhood Leukemia
|
NCI
|
1R01CA131081-01
|
|
Disrupting the AF4-AF9 protein complex in MLL leukemias.
|
HEMENWAY, CHARLES
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$129,195
|
|
Childhood Leukemia
|
NIAID
|
5R01AI026782-18
|
|
LY-1 B Cells: Developmental Origins and V Gene Biases
|
HARDY, RICHARD
|
INSTITUTE FOR CANCER RESEARCH
|
PA
|
$558,031
|
|
Childhood Leukemia
|
NIAID
|
5R01AI058162-05
|
|
Developmental Stage-Related Changes in Lymphopoiesis
|
KINCADE, PAUL
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$359,276
|
|
Childhood Leukemia
|
NCI
|
2P01CA070970-10A1
|
0004
|
Flt3: Role in Leukemia Stem Cells
|
SMALL, DONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$324,674
|
|
Childhood Leukemia
|
NCI
|
5R01CA104962-03
|
|
The molecular role of lkaros in leukemogenesis
|
WINANDY, SUSAN
|
NORTHWESTERN UNIVERSITY
|
IL
|
$227,542
|
|
Childhood Leukemia
|
NCI
|
5R01CA113930-03
|
|
Metabolic Syndrome in Childhood Cancer Survivors
|
STEINBERGER, JULIA
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$504,537
|
|
Childhood Leukemia
|
NCI
|
5R01CA114199-04
|
|
Src Kinases in Ph+ Lymphoblastic Leukemia
|
LI, SHAOGUANG
|
JACKSON LABORATORY
|
ME
|
$284,832
|
|
Childhood Leukemia
|
NCI
|
5R01CA114589-04
|
|
Microenvironmental mechanisms of leukemia cell survival
|
LARSON, RICHARD
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$224,720
|
|
Childhood Leukemia
|
NCI
|
5R01CA118319-03
|
|
The Role of CBFb-MYH11 in Acute Myeloid Leukemia
|
MULLOY, JAMES
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$371,211
|
|
Childhood Leukemia
|
NCI
|
1R01CA123014-01A2
|
|
Genomic instability causes imatinib resistance in CML
|
SKORSKI, TOMASZ
|
TEMPLE UNIVERSITY
|
PA
|
$297,995
|
|
Childhood Leukemia
|
NCI
|
2R01CA090668-06A1
|
|
FLT3 Tyrosine Kinase Inhibitors as Therapy for Leukemia
|
SMALL, DONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$293,612
|
|
Childhood Leukemia
|
NCI
|
2R01CA056876-15A1
|
|
Hoxa9, Meis1, and Pbx in Self-renewal and Leukemogenesis
|
KAMPS, MARK
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$378,793
|
|
Childhood Leukemia
|
NCI
|
1R21CA128019-01A1
|
|
PACE-CALL: A Weight Control Intervention for Survivors of Childhood Leukemia
|
PATRICK, KEVIN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$208,575
|
|
Childhood Leukemia
|
NCI
|
5R01CA087549-09
|
|
Mechanism of inv(16) mediated leukemogenesis
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
TN
|
$405,438
|
|
Childhood Leukemia
|
NINDS
|
5K24NS048323-05
|
|
Cerebrovascular Disease in Sickle Cell Anemia
|
LERNER, NORMA
|
UNIVERSITY OF ROCHESTER
|
NY
|
$120,711
|
|
Childhood Leukemia
|
NHLBI
|
5R01HL088494-02
|
|
Function of MTG16/ETO2 in acute leukemia
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
TN
|
$383,750
|
|
Childhood Leukemia
|
NCI
|
2P01CA066996-11A1
|
0008
|
TYROSINE KINASE ONCOGENES IN ACUTE MYELOID LEUKEMIAS
|
GRIFFIN, JAMES
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$302,258
|
|
Childhood Leukemia
|
NCI
|
2P01CA066996-11A1
|
0009
|
ONCOGENESIS AND MYELOID TRANSCRIPTION FACTORS IN AML
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$513,821
|
|
Childhood Leukemia
|
NCI
|
2P01CA066996-11A1
|
0012
|
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS
|
ARMSTRONG, SCOTT
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$510,801
|
|
Childhood Leukemia
|
NCI
|
5R01CA096798-05
|
|
Analysis of a murine model of the AML1-ETO translocation
|
KLUG, CHRISTOPHER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$281,848
|
|
Childhood Leukemia
|
NCI
|
5R01CA116660-02
|
|
Determinants of Relapse Risk After BMT for ALL
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$289,644
|
|
Childhood Leukemia
|
NCI
|
5R01CA108862-04
|
|
GENETIC PREDICTORS OF LEUKEMIA THERAPY RESPONSE
|
APLENC, RICHARD
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$255,452
|
|
Childhood Leukemia
|
NCI
|
5R01CA115772-03
|
|
Molecular Analysis of Del(9q) Acute Myeloid Leukemia
|
SWEETSER, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$395,847
|
|
Childhood Leukemia
|
NCI
|
5R01CA098152-06
|
|
Molecular Determinants of Methotrexate in Acute Lymphoblastic Leukemia
|
BARREDO, JULIO
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$297,398
|
|
Childhood Leukemia
|
NCI
|
5R21CA119142-02
|
|
Variation in Ara-C Pathway Genes and Treatment Outcomes in AML
|
GOYAL, RAKESH
|
CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
|
PA
|
$152,926
|
|
Childhood Leukemia
|
NIEHS
|
5F30ES015668-02
|
|
The Protein Kinase C Pathway In Acute Leukemia
|
REDIG, AMANDA
|
NORTHWESTERN UNIVERSITY
|
IL
|
$27,688
|
|
Childhood Leukemia
|
NCI
|
5R01CA116750-03
|
|
Health Promotion in Minority Childhood Cancer Survivors
|
STOLLEY, MELINDA
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$262,705
|
|
Childhood Leukemia
|
NCI
|
5R01CA090576-09
|
|
Studies of BCR/ABL Leukemogenesis in Mice
|
VAN ETTEN, RICHARD
|
TUFTS MEDICAL CENTER
|
MA
|
$286,110
|
|
Childhood Leukemia
|
NCI
|
5R01CA096899-05
|
|
Mechanism(s) of TAL-1/SCL-mediated Leukemogenesis
|
KELLIHER, MICHELLE
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$315,864
|
|
Childhood Leukemia
|
NCI
|
5R01CA104449-05
|
|
MLL Fusions and cooperating mutations in acute leukemia
|
THIRMAN, MICHAEL
|
UNIVERSITY OF CHICAGO
|
IL
|
$296,426
|
|
Childhood Leukemia
|
NCI
|
5R01CA055029-18
|
|
Pathology and Biology of Leukemia Oncogenes
|
CLEARY, MICHAEL
|
STANFORD UNIVERSITY
|
CA
|
$366,118
|
|
Childhood Leukemia
|
NCI
|
5R01CA115422-03
|
|
Clinical Significance of Residual Myeloid Leukemia
|
CAMPANA, DARIO
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$260,208
|
|
Childhood Leukemia
|
NCI
|
5R01CA102646-04
|
|
USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$311,617
|
|
Childhood Leukemia
|
NCI
|
5R01CA104666-04
|
|
Genetic Consequences of Therapies for Cancer
|
BOICE, JOHN
|
VANDERBILT UNIVERSITY
|
TN
|
$575,969
|
|
Childhood Leukemia
|
NCI
|
5R01CA114945-11
|
|
Role of Gab2 and Shp2 in Hematopoietic Signalling
|
NEEL, BENJAMIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$396,987
|
|
Childhood Leukemia
|
NIGMS
|
5R01GM074691-03
|
|
Copolymer hydrogel microspheres for analysis of kinase activity in cell lysates
|
PALECEK, SEAN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$240,772
|
|
Childhood Leukemia
|
NCI
|
5R01CA087053-08
|
|
MLL AF4 Leukemia
|
KERSEY, JOHN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$265,167
|
|
Childhood Leukemia
|
NCI
|
5R21CA122117-02
|
|
Evaluation of resveratrol and curcumin as therapeutics against high-risk leukemia
|
ZUNINO, SUSAN
|
U.S. AGRICULTURAL RESEARCH SERVICE
|
CA
|
$100,000
|
|
Childhood Leukemia
|
NINR
|
5R01NR008570-04
|
|
Chemotherapy, Pain, Sleep, Fatigue in Children & Parents
|
GEDALY-DUFF, VIVIAN
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$346,716
|
|
Childhood Leukemia
|
NIEHS
|
5R01ES009137-10
|
|
Childhood Leukemia and Environmental Exposures
|
BUFFLER, PATRICIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$892,145
|
|
Childhood Leukemia
|
NCI
|
5R37CA036401-25
|
|
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)
|
EVANS, WILLIAM
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$576,724
|
|
Childhood Leukemia
|
NCI
|
5R01CA086017-09
|
|
Molecular characterization of Acute Myeloid Leukemia
|
WEISSMAN, IRVING
|
STANFORD UNIVERSITY
|
CA
|
$371,325
|
|
Childhood Leukemia
|
NCI
|
5U01CA114762-04
|
|
Leukemia Signatures for Risk Classification & Targeting
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$1,402,928
|
|
Childhood Leukemia
|
NCI
|
5R01CA096670-05
|
|
Ethnic Differences in Survival after Childhood ALL
|
BHATIA, SMITA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$488,086
|
|
Childhood Leukemia
|
NIEHS
|
1K99ES016585-01
|
|
Environmental Influence on T-Cell Leukemia: Role of Notch and AhR Signaling
|
LAIOSA, MICHAEL
|
UNIVERSITY OF ROCHESTER
|
NY
|
$97,200
|
|
Childhood Leukemia
|
NCI
|
1K08CA133103-01
|
|
Zebrafish Chemical and Classical Genetics Approach to the Pathogenesis of T-ALL
|
GUTIERREZ, ALEJANDRO
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$140,940
|
|
Childhood Leukemia
|
NCI
|
5R01CA109281-05
|
|
Mechanisms of Leukemogenic Transformation by MLL-CALM
|
WECHSLER, DANIEL
|
DUKE UNIVERSITY
|
NC
|
$262,921
|
|
Childhood Leukemia
|
NCI
|
5R01CA101774-06
|
|
Mechanisms of Leukemogenesis in Down Syndrome
|
CRISPINO, JOHN
|
NORTHWESTERN UNIVERSITY
|
IL
|
$305,841
|
|
Childhood Leukemia
|
NCI
|
5K22CA113557-03
|
|
Ras Pathway Mutations in Human Leukemia
|
LOH, MIGNON
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$149,175
|
|
Childhood Leukemia
|
NCI
|
5R03CA130030-02
|
|
Oxygen and Phototherapy in perinatal period: Risk of Acute Lymphoctyic Leukemia
|
PANETH, NIGEL
|
MICHIGAN STATE UNIVERSITY
|
MI
|
$76,000
|
|
Childhood Leukemia
|
NCI
|
5R01CA086011-08
|
|
Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
|
BOROWITZ, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$546,364
|
|
Childhood Leukemia
|
NINR
|
5R01NR009409-03
|
|
A Decision Aid for Cancer-Surviving Adolescents
|
HOLLEN, PATRICIA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$338,746
|
|
Childhood Leukemia
|
NCI
|
5R01CA072996-12
|
|
Role of MN1-TEL and MN1 in Leukemogenesis
|
GROSVELD, GERARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$333,189
|
|
Childhood Leukemia
|
NCI
|
5K12CA090433-07
|
|
Pediatric Clinical Oncology Research Training Program
|
POPLACK, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$707,872
|
|
Childhood Leukemia
|
NCI
|
2R01CA095512-05A1
|
|
Role of RNA Binding Proteins in BCR/ABL Leukemogenesis
|
PERROTTI, DANILO
|
OHIO STATE UNIVERSITY
|
OH
|
$250,821
|
|
Childhood Leukemia
|
NCI
|
5R01CA120772-02
|
|
Molecular and Pharmacologic Correletes of Acute Myeloid Leukemia in Down Syndrome
|
TAUB, JEFFREY
|
WAYNE STATE UNIVERSITY
|
MI
|
$406,183
|
|
Childhood Leukemia
|
NCI
|
1R01CA128864-01A1
|
|
Incorporating FLT3 inhibitors into AML treatment regimens
|
LEVIS, MARK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$340,300
|
|
Childhood Leukemia
|
NCI
|
2P01CA101937-05A1
|
0004
|
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis
|
TOMASSON, MICHAEL
|
WASHINGTON UNIVERSITY
|
MO
|
$281,421
|
|
Childhood Leukemia
|
NCI
|
2P50CA100632-06
|
0004
|
Incorporating FLT3 Inhibitors into AML Treatment Regimens
|
LEVIS, MARK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$267,743
|
|
Childhood Leukemia
|
NHLBI
|
5R21HL082670-02
|
|
SHP-2 Inhibitors as Potential Therapeutic Agents for JMML and Noonan Syndrome
|
QU, CHENG-KUI
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$228,162
|
|
Childhood Leukemia
|
NCI
|
5R01CA115665-03
|
|
Molecular Mechanisms of Lymphomagenesis
|
MILLS, KEVIN
|
JACKSON LABORATORY
|
ME
|
$289,553
|
|
Childhood Leukemia
|
NCI
|
5R03CA125823-02
|
|
MHC Genetic Variation, Exposure to Infections and Risk of Childhood Leukemia
|
BUFFLER, PATRICIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$62,555
|
|
Childhood Leukemia
|
NCI
|
5K08CA101934-06
|
|
Notch-Mediated Apoptosis in Human B Cell Malignancies
|
ZWEIDLER-MCKAY, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$136,080
|
|
Childhood Leukemia
|
NCI
|
5R01CA114563-04
|
|
Biology and Prognostic implications of Flt3 mutations in AML
|
MESHINCHI, SOHEIL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$422,916
|
|
Childhood Leukemia
|
NCI
|
5K08CA119105-03
|
|
Modeling Multi-step Leukemogenesis in Nf1 and Kras Mutant Mice
|
LAUCHLE, JENNIFER
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$127,170
|
|
Childhood Leukemia
|
NCI
|
5R01CA120583-02
|
|
Antileukemic effort of NK cells in HCT for pediatric AML
|
LEUNG, WING
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$364,712
|
|
Childhood Leukemia
|
NCI
|
5K08CA104882-05
|
|
ROLE OF mTOR INHIBITORS AND IL7 IN LYMPHOID MALIGNANCIES
|
BROWN, VALERIE
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$138,672
|
|
Childhood Leukemia
|
NCI
|
2R13CA095124-04
|
|
Long-Term Complications of Children/Adolescents & Cancer
|
GREEN, DANIEL
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$15,618
|
|
Childhood Leukemia
|
NCI
|
5R01CA090321-07
|
|
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs
|
HEISTERKAMP, NORA
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$266,679
|
|
Childhood Leukemia
|
NCI
|
5R01CA128609-03
|
|
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
OH
|
$300,246
|
|
Childhood Leukemia
|
NCI
|
5K23CA120708-03
|
|
Experimental Therapeutics in Acute Leukemias
|
BLUM, WILLIAM
|
OHIO STATE UNIVERSITY
|
OH
|
$129,720
|
|
Childhood Leukemia
|
NCI
|
5U10CA052771-18
|
|
South Texas Pediatric Minority Based CCOP
|
LANGEVIN, ANNE-MARIE
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$509,502
|
|
Childhood Leukemia
|
NCI
|
5R01CA111468-03
|
|
Enhancement of methotrexate uptake in childhood ALL
|
MCGUIRE, JOHN
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$305,489
|
|
Childhood Leukemia
|
NCI
|
5R01CA118580-02
|
|
Parental genotypes and exposures in sporadic retinoblastoma
|
GANGULY, ARUPA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$567,617
|
|
Childhood Leukemia
|
NHLBI
|
5R01HL082981-04
|
|
Activating PTPN11 and c-kit Mutations in Myeloproliferative Disorder
|
CHAN, REBECCA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$357,938
|
|
Childhood Leukemia
|
NCI
|
5R01CA124633-02
|
|
Pathogenesis of NUT-Rearranged Carcinoma
|
FRENCH, CHRISTOPHER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$299,250
|
|
Childhood Leukemia
|
NCI
|
5K23CA111728-03
|
|
Developing FLT3-Targeted Therapy for Pediatric Leukemia
|
BROWN, PATRICK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$140,130
|
|
Childhood Leukemia
|
NCI
|
5R21CA126457-02
|
|
Phase I study of 5-aza-2?-deoxycitidine in acute lymphocytic leukemia
|
GARCIA-MANERO, GUILLERMO
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$292,600
|
|
Childhood Leukemia
|
NCI
|
5K22CA120626-02
|
|
TEL-AML1 Transgenic Zebrafish Model of Human Leukemia
|
SABAAWY, HATEM
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$162,960
|
|
Childhood Leukemia
|
NCI
|
5R13CA132568-02
|
|
International Symposium on Juvenile Myelomonocytic Leukemia
|
LOH, MIGNON
|
JMML FOUNDATION
|
CA
|
$7,500
|
|
Childhood Leukemia
|
OD
|
5R13CA132568-02
|
|
International Symposium on Juvenile Myelomonocytic Leukemia
|
LOH, MIGNON
|
JMML FOUNDATION
|
CA
|
$20,000
|
|
Childhood Leukemia
|
NCI
|
5R01CA122142-02
|
|
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia
|
LI, SHAOGUANG
|
JACKSON LABORATORY
|
ME
|
$330,600
|
|
Childhood Leukemia
|
NCI
|
5R01CA127642-02
|
|
Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
|
LIPSHULTZ, STEVEN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$323,497
|
|
Childhood Leukemia
|
NCI
|
5R03CA132570-02
|
|
TRICCS: Targeting Inattention in Childhood Cancer Survivors
|
HARDY, KRISTINA K.
|
DUKE UNIVERSITY
|
NC
|
$78,000
|
|
Childhood Leukemia
|
NCI
|
5R01CA125671-02
|
|
Perceived Cognitive function Item Bank for Children Who Undergo Cancer Treatment
|
LAI, JIN-SHEI
|
EVANSTON NORTHWESTERN HEALTHCARE
|
IL
|
$452,038
|
|
Childhood Leukemia
|
NCI
|
5R01CA119162-02
|
|
Promoting Treatment Adherence in Adolescent Leukemia
|
DROTAR, DENNIS
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$648,827
|
|
Childhood Leukemia
|
NCI
|
5R03CA132172-02
|
|
Childhood Leukemia International Consortium (CLIC)
|
BUFFLER, PATRICIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$62,396
|
|
Childhood Leukemia
|
NCRR
|
5K23RR023328-02
|
|
Proteomic and computational methods in pediatric acute lymphoblastic leukemia
|
CZADER, MAGDALENA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$110,953
|
|
Childhood Leukemia
|
NCI
|
1K08CA134649-01
|
|
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
|
LI, QING
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$127,170
|
|
Childhood Leukemia
|
NCI
|
1R01CA130867-01A1
|
|
Identifying genetic mechanisms in T-ALL with an inducible Sleeping Beauty system
|
DUPUY, ADAM
|
UNIVERSITY OF IOWA
|
IA
|
$311,250
|
|
Childhood Leukemia
|
NCI
|
2R01CA102463-05A1
|
|
Mechanism of Action of TOP2-Directed Anticancer Drugs
|
LIU, LEROY
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$281,093
|
|
Childhood Leukemia
|
NHLBI
|
1R01HL090589-01A1
|
|
Transcriptional regulation of TAL1/SCL in normal and malignant hematopoiesis
|
HUANG, SUMING
|
UNIVERSITY OF FLORIDA
|
FL
|
$363,269
|
|
Childhood Leukemia
|
NCI
|
1R43CA135984-01
|
|
Familias Fuertes: Outreach to Latino families with a child coping with cancer
|
HOLTZ, KRISTEN
|
KDH RESEARCH AND COMMUNICATION, INC.
|
GA
|
$113,988
|
|
Childhood Leukemia
|
OD
|
3R13CA132568-01S1
|
|
International Symposium on Juvenile Myelomonocytic Leukemia
|
LOH, MIGNON
|
JMML FOUNDATION
|
CA
|
$20,000
|
|
Childhood Leukemia
|
NCI
|
3R01CA090321-06A1S1
|
|
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs
|
HEISTERKAMP, NORA
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$42,525
|
|
Childhood Leukemia
|
NCI
|
1R03CA133960-01A1
|
|
Risk Factors for TEL-AML Fusion Genes and Childhood Acute Lymphoblastic Leukemia
|
EZZAT, SAMEERA
|
NATL HEPATOLOGY/TROPICAL MED RES INST
|
EGYPT
|
$54,000
|
|
Childhood Leukemia
|
NIEHS
|
5P42ES004705-21
|
0023
|
Project 1: Biomarkers of Chemical Exposure and Leukemia Risk
|
BUFFLER, PATRICIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$420,392
|
|
Childhood Leukemia
|
NCI
|
1P20CA137219-01
|
0004
|
Developmental Program
|
DEARING, JAMES
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
CA
|
$90,243
|
|
Childhood Leukemia
|
NCI
|
5P30CA082103-10
|
0021
|
PEDIATRIC MALIGNANCIES PROGRAM
|
MATTHAY, KATHERINE
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$70,316
|
|
Childhood Leukemia
|
NCI
|
5P01CA044991-21
|
0003
|
Radiolabeled Antibody Therapy of Acute Leukemia
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$461,778
|
|
Childhood Leukemia
|
OD
|
2R56CA100159-05
|
|
Etiology of translocations in hematopoietic cells
|
RICHARDSON, CHRISTINE
|
UNIVERSITY OF NORTH CAROLINA CHARLOTTE
|
NC
|
$263,952
|
|
Childhood Leukemia
|
NCI
|
1R01CA138237-01
|
|
Fanconi Anemia stem cells allow molecular characterization of acute leukemia
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$397,686
|
|
Childhood Leukemia
|
NCI
|
5P01CA068484-13
|
0011
|
Discovery of New Therapeutic Targets in ALL
|
GILLILAND, GARY
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$605,214
|
|
Childhood Leukemia
|
NCI
|
5P01CA068484-13
|
0012
|
Modeling Childhood TEL-AML1 (Runx1)
|
ORKIN, STUART
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$173,664
|
|
Childhood Leukemia
|
NCI
|
5P01CA068484-13
|
0014
|
Anti-ALL Small Molecular Discovery via Chemical Genomics
|
GOLUB, TODD
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$235,053
|
|
Childhood Leukemia
|
NCI
|
5P01CA068484-13
|
0016
|
Treatment of Childhood and Adult ALL
|
SILVERMAN, LEWIS
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$238,374
|
|
Childhood Leukemia
|
NCI
|
5P01CA068484-13
|
9001
|
Clinical Consortia (Pediatric & Adult)
|
SALLAN, STEPHEN
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$489,222
|
|
Childhood Leukemia
|
NCI
|
5P01CA105049-04
|
0002
|
MLL-FUSIONS AND COOPERATING MUTATIONS IN ACUTE LEUKEMIA
|
THIRMAN, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$278,965
|
|
Childhood Leukemia
|
NCI
|
3U10CA052771-18S1
|
|
South Texas Pediatric Minority Based CCOP
|
LANGEVIN, ANNE-MARIE
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$84,400
|
|
Childhood Leukemia
|
NCI
|
3R37CA036401-25S1
|
|
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)
|
EVANS, WILLIAM
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$396,000
|
|
Childhood Leukemia
|
NCI
|
3R01CA096735-06S1
|
|
T(8;21) in Blood Cell Proliferation and Differentiation
|
ZHANG, DONG-ER
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$63,345
|
|
Childhood Leukemia
|
NCRR
|
5M01RR000082-46
|
7206
|
TRANSFUSION OF AUTOLOGOUS UMBILICAL CORD BLOOD TO REV HYPERGLYCEMIA IN CHILDREN
|
HALLER, MICHAEL
|
UNIVERSITY OF FLORIDA
|
FL
|
$70,999
|
|
Childhood Leukemia
|
NCRR
|
5M01RR000400-40
|
7558
|
NEUROIMAGING AND COGNITIVE CHANGES IN CHILDHOOD LEUKEMIA SURVIVORS
|
ANDERSON, FIONA
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$7,510
|
|
Childhood Leukemia
|
NCRR
|
5M01RR000750-36
|
7621
|
SERUM BANKING FOR SERUM PROTEIN PROFILING OF CHILDHOOD CANCER
|
RAGG, SUSANNE
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$3,708
|
|
Childhood Leukemia
|
NCRR
|
5M01RR000188-44
|
7817
|
CLINICAL TRIAL: A PHASE I STUDY OF BMS-354825 IN CHILDREN WITH RECURRENT/REFRACT
|
BLANEY, SUSAN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$2,900
|
|
Childhood Leukemia
|
NCRR
|
5M01RR000188-44
|
7836
|
CLINICAL TRIAL: A PHASE I/II SAFETY AND EXPLORATORY PHARMACODYNAMIC STUDY OF INT
|
BLANEY, SUSAN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$15,839
|
|
Childhood Leukemia
|
NCRR
|
5P20RR020152-05
|
6902
|
TULANE CANCER GENETICS COBRE: INOVATIVE THERAPIES FOR T(4;11) LEUKEMIA
|
HEMENWAY, CHARLES
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$28,213
|
|
Childhood Leukemia
|
NCRR
|
5P41RR006009-18
|
5434
|
NOVEL SMALL MOLECULES FOR INVESTIGATING MECHANISMS OF MLL-CBP-INDUCED LEUKEMIA
|
RODRIGUEZ, YOEL
|
CARNEGIE-MELLON UNIVERSITY
|
PA
|
$473
|
|
Childhood Leukemia
|
NCRR
|
5P41RR011823-13
|
5877
|
SEARCH AML1-ETO INTERACTING PROTEIN
|
ZHANG, DONG-ER
|
UNIVERSITY OF WASHINGTON
|
WA
|
$8,075
|
|
Childhood Leukemia
|
NCI
|
5P01CA055164-16
|
0018
|
MicroRNA"s in the Treatment of AML
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
OH
|
$294,594
|
|
Childhood Leukemia
|
NCI
|
5P01CA103985-04
|
8070
|
Radioimmunotherapy of B-cell Malignancies
|
MATTES, M
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
NJ
|
$108,384
|
|
Childhood Leukemia
|
NCI
|
1Z01SC006830-38
|
|
Treatment of Infections in Immunocompromised Children
|
WALSH, THOMAS
|
NIH
|
|
$2,609,501
|
|
Childhood Leukemia
|
NCI
|
1Z01SC009431-14
|
|
Histologic and Molecular Characterization of Solid Pediatric Tumors
|
TSOKOS, MARIA
|
NIH
|
|
$316,500
|
|
Childhood Leukemia
|
NCI
|
1Z01SC010353-09
|
|
Experimental Therapeutics of Pediatric Hematopoietic Malignancies
|
WAYNE, ALAN
|
NIH
|
|
$1,135,420
|
|
Childhood Leukemia
|
NCI
|
1Z01SC010354-09
|
|
Clinical Development of Novel Drugs for Children with Refractory Cancers
|
WIDEMANN, BRIGITTE
|
NIH
|
|
$142,432
|
